Valuation: EyePoint, Inc.

Market Cap 116.21Cr 100.73Cr 94Cr 86Cr 162.01Cr 11TCr 164.61Cr 1.11TCr 434.08Cr 5.55TCr 436.3Cr 426.85Cr 19TCr P/E 2026 *
-3.53x
P/E 2027 * -4.52x
Enterprise Value 84Cr 73Cr 68Cr 62Cr 117.01Cr 8.01TCr 118.89Cr 803.05Cr 313.51Cr 4.01TCr 315.12Cr 308.29Cr 13TCr EV / Sales 2026 *
478x
EV / Sales 2027 * 36.5x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day+1.30%
1 week-2.81%
Current month+10.20%
1 month-1.68%
3 months+1.96%
6 months-9.46%
Current year-26.11%
1 week 12.37
Extreme 12.37
14.32
1 month 11.54
Extreme 11.54
14.32
Current year 11.3
Extreme 11.295
18.87
1 year 9.65
Extreme 9.65
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
41.5
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/06/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
23/03/26 Others

Chief Executive Officer

4,53,532 0.5478%
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-2.81%+24.42%-4.93% 116.21Cr
-2.09%-0.45%+72.46%+119.40% 1,07800Cr
-0.54%+0.46%+49.06%+50.16% 63TCr
-0.81%+1.60%+22.13%+64.17% 44TCr
-2.25%-3.81%+41.26%+33.40% 36TCr
-1.83%-3.68%+23.10%+33.46% 29TCr
-1.95%-3.75%-1.17%+3.02% 25TCr
-1.39%+0.21%+41.86%+57.80% 23TCr
-0.54%-2.47%-8.31%-51.95% 20TCr
-0.77%+2.76%+15.01%+71.42% 17TCr
Average -1.12%+1.80%+27.98%+37.59% 36.45TCr
Weighted average by Cap. -1.52%+1.30%+41.24%+61.95%

Financials

2026 *2027 *
Net sales 17.55L 15.21L 14.26L 13L 24.46L 17Cr 24.86L 1.68Cr 65.55L 8.38Cr 65.88L 64.46L 28Cr 2.19Cr 1.9Cr 1.78Cr 1.62Cr 3.06Cr 209.18Cr 3.1Cr 21Cr 8.19Cr 104.71Cr 8.23Cr 8.05Cr 349.3Cr
Net income -34Cr -30Cr -28Cr -25Cr -48Cr -3.28TCr -49Cr -329.11Cr -128.48Cr -1.64TCr -129.14Cr -126.35Cr -5.48TCr -29Cr -25Cr -24Cr -21Cr -40Cr -2.76TCr -41Cr -276.97Cr -108.13Cr -1.38TCr -108.68Cr -106.33Cr -4.61TCr
Net Debt -32Cr -28Cr -26Cr -24Cr -45Cr -3.08TCr -46Cr -308.84Cr -120.57Cr -1.54TCr -121.19Cr -118.56Cr -5.14TCr -36Cr -31Cr -29Cr -27Cr -50Cr -3.45TCr -51Cr -346.3Cr -135.2Cr -1.73TCr -135.89Cr -132.95Cr -5.77TCr
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
-
Date Price Change Volume
14/26/14 $13.50 +0.15% 51,676
13/26/13 $13.48 -0.37% 12,02,186
12/26/12 $13.53 +3.68% 22,61,368
11/26/11 $13.05 -0.15% 20,58,473
10/26/10 $13.07 -5.90% 17,57,173
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
13.48USD
Average target price
40.93USD
Spread / Average Target
+203.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock